• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Infectious Diseases and Therapy >Rapid and Effective Virucidal Activity of Povidone-Iodine Products Against Middle East Respiratory Syndrome Coronavirus (MERS-CoV) and Modified Vaccinia Virus Ankara (MVA)
【24h】

Rapid and Effective Virucidal Activity of Povidone-Iodine Products Against Middle East Respiratory Syndrome Coronavirus (MERS-CoV) and Modified Vaccinia Virus Ankara (MVA)

机译：聚维酮碘产品对中东呼吸系统综合症冠状病毒（MERS-CoV）和修饰的痘苗病毒安卡拉（MVA）的快速有效杀病毒活性

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Introduction Since the first case of Middle East Respiratory Syndrome coronavirus (MERS-CoV) infection was reported in 2012, the virus has infected more than 1300 individuals in 26 countries, and caused more than 480 deaths. Human-to-human transmission requires close contact, and has typically occurred in the healthcare setting. Improved global awareness, together with improved hygiene practices in healthcare facilities, has been highlighted as key strategies in controlling the spread of MERS-CoV. This study tested the in vitro efficacy of three formulations of povidone iodine (PVP-I: 4% PVP-I skin cleanser, 7.5% PVP-I surgical scrub, and 1% PVP-I gargle/mouthwash) against a reference virus (Modified vaccinia virus Ankara, MVA) and MERS-CoV. Methods According to EN14476, a standard suspension test was used to assess virucidal activity against MVA and large volume plating was used for MERS-CoV. All products were tested under clean (0.3?g/L bovine serum albumin, BSA) and dirty conditions (3.0?g/L BSA?+?3.0?mL/L erythrocytes), with application times of 15, 30, and 60?s for MVA, and 15?s for MERS-CoV. The products were tested undiluted, 1:10 and 1:100 diluted against MVA, and undiluted against MERS-CoV. Results A reduction in virus titer of ≥4 log10 (corresponding to an inactivation of ≥99.99%) was regarded as evidence of virucidal activity. This was achieved versus MVA and MERS-CoV, under both clean and dirty conditions, within 15?s of application of each undiluted PVP-I product. Conclusion These data indicate that PVP-I-based hand wash products for potentially contaminated skin, and PVP-I gargle/mouthwash for reduction of viral load in the oral cavity and the oropharynx, may help to support hygiene measures to prevent transmission of MERS-CoV. Funding Mundipharma Research GmbH & Co.
机译：简介自2012年报道第一例中东呼吸综合征冠状病毒（MERS-CoV）感染以来，该病毒已感染26个国家的1300多人，造成480多人死亡。人与人之间的传播需要密切接触，并且通常发生在医疗机构中。作为控制MERS-CoV传播的关键策略，人们强调了提高全球意识以及改善医疗机构的卫生习惯。这项研究测试了三种聚维酮碘制剂（PVP-1：4％PVP-1皮肤清洁剂，7.5％PVP-1外科手术擦洗液和1％PVP-1含漱液/漱口水）对参考病毒的体外功效（改良牛痘病毒安卡拉（MVA）和MERS-CoV。方法根据EN14476，使用标准悬浮液测试评估对MVA的杀灭活性，对MERS-CoV使用大体积电镀。所有产品均在干净（0.3？g / L牛血清白蛋白，BSA）和肮脏条件（3.0？g / L BSA？+？3.0？mL / L红细胞）下测试，施用时间分别为15、30和60?。 MVA为s，MERS-CoV为15s。将产品未经稀释进行测试，以MVA稀释为1:10和1：100，并以MERS-CoV进行稀释。结果病毒滴度降低≥4log 10 （相当于灭活≥99.99％）被视为具有杀病毒活性。与MVA和MERS-CoV相比，在清洁和肮脏的条件下，在未稀释的每种PVP-I产品施用后15秒内即可实现这一目标。结论这些数据表明，针对潜在污染皮肤的基于PVP-1的洗手产品，以及用于降低口腔和口咽中病毒载量的PVP-1含漱液/漱口水，可能有助于支持卫生措施以防止MERS-冠状病毒资助Mundipharma Research GmbH＆Co.

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号